CD274 and non-small cell lung carcinoma: Another traditional meta-analysis also focused on the resectable NSCLC population, comparing the efficacy and safety of PD-1 and PD-L1 inhibitors as neoadjuvant therapy and neoadjuvant therapy plus adjuvant treatment.